Anti-Obesity Drug Market Analysis & Forecast: 2025-2032

Global Anti-Obesity Drug Market Size and Forecast 

The Global Anti-Obesity Drug Market is estimated to be valued at USD 25.87 Bn in 2025 and is expected to reach USD 82.55 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032. This significant growth reflects the increasing global prevalence of obesity and rising demand for effective pharmaceutical interventions. Innovations in drug formulations and expanding healthcare infrastructure in emerging markets also contribute to the robust market expansion over the forecast period.

Key Takeaways of the Global Anti-Obesity Drug Market

• In the global anti-obesity drug market, prescription drugs are expected to hold the largest share, accounting for 65.1% in 2025.
• Among various drug classes, GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists are projected to lead, capturing 22.1% of the market share in 2025.
• In terms of route of administration routes, the oral segment is forecast to hold the largest share at 32.1% in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.2% in 2025.

Market Overview

Market trends indicate a strong shift towards personalized medicine and combination therapies in the anti-obesity drug sector, driven by a better understanding of obesity’s multifactorial nature. Additionally, increasing investments in research and development are fueling the introduction of novel drugs with improved efficacy and safety profiles. Digital health integration, such as mobile health apps for monitoring and adherence, is further enhancing patient outcomes, while growing awareness about obesity-related health risks is driving demand across both developed and developing regions.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Anti-Obesity Drug Market Insights, By Drug Type - Prescription drugs dominate due to their proven efficacy in managing obesity and their ability to provide targeted, long-term solutions

In terms of drug type, the prescription drugs segment is expected to contribute the highest share of the global anti-obesity drug market with a share of 65.1% in 2025 owing to multiple critical factors that underscore their widespread adoption and acceptance. Primarily, prescription drugs benefit from rigorous clinical validation, ensuring higher efficacy and safety profiles than Over-the-Counter (OTC) alternatives. This guarantees greater confidence among healthcare professionals when recommending these treatments to patients. The increasing prevalence of obesity-related comorbidities such as diabetes, cardiovascular diseases, and hypertension has escalated the demand for more potent and targeted therapies, roles best fulfilled by prescription drugs.

According to a study by BMC Public Health, in January 2025, the escalating prevalence of obesity-related comorbidities, particularly type 2 diabetes, is a growing global health concern. Research indicates that obesity is linked to 30–53% of new diabetes cases annually in the U.S. Similarly, in India, obesity is a significant risk factor for diabetes, with approximately 26% of the global diabetic population residing in the country.

Clinical advancements in prescription formulations have notably enhanced patient adherence and outcomes, with many drugs offering multifaceted mechanisms that precisely target metabolic pathways responsible for weight gain. Government and private health insurance support often cover these prescription medications, making them more accessible to a broader demographic, especially in countries with well-established healthcare infrastructure. Conversely, OTC drugs are frequently limited by their milder efficacy and regulatory constraints, which restrict their use for more severe or complex obesity cases.

Anti-Obesity Drug Market Insights, by Drug Class - GLP-1 receptor agonists lead due to targeting metabolic control

Within the global anti-obesity drug market segmented by drug class, GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists hold the highest share with an estimated 22.1% in 2025, driven largely by their dual role in appetite regulation and glucose metabolism. These agents mimic the incretin hormones, which enhance insulin secretion and suppress glucagon release, leading to potent effects on weight reduction and glycemic control. This makes GLP-1 receptor agonists particularly attractive for patients with obesity complicated by type 2 diabetes, establishing them as a cornerstone treatment option.

The significant success of key drugs like Semaglutide, Liraglutide, and Tirzepatide illustrates the segment’s appeal. These therapies not only contribute to substantial and sustained weight loss but also improve cardiovascular health markers, which is crucial for obese individuals facing elevated risks of heart disease. Their multifaceted benefits extend beyond mere weight management, encompassing improved metabolic profiles that reduce long-term health risks.

In April 2025, according to an article published by the Heart Rhythm Society, a recent clinical study, TRANSFORM-AF, found that GLP-1 receptor agonists (GLP-1 RAs), typically used for diabetes, may reduce atrial fibrillation (AF)-related events in patients with both obesity and AF. Conducted across 170 Veterans Affairs hospitals, the study showed a 13% reduction in major AF-related events, including hospitalizations and ablation procedures, with the greatest benefits seen in patients with severe obesity.

Anti-Obesity Drug Market Insights, By Route of Administration - Oral administration dominates due to convenience and compliance

By route of administration, the oral segment is expected to command the highest share in the global anti-obesity drug market with 32.1% in 2025, predominantly because of patient preference and its convenience in daily use. Oral medications provide a non-invasive, easily self-administered option that significantly improves adherence, particularly for long-term weight management where continuous treatment is often necessary.

Patients generally favor oral anti-obesity drugs as they reduce the discomfort and complexity associated with injectables or transdermal patches, allowing for discreet and flexible dosing. The global rise in telehealth consultations and online pharmacies further boosts accessibility to oral formulations, overcoming geographical and logistical barriers. In addition, many oral drugs exhibit favorable stability and shelf life, ensuring easier storage and transportation across diverse markets.

Regional Insights

To learn more about this report, Download Free Sample

North America Anti-Obesity Drug Market Analysis and Trends

North America’s dominance in the global anti-obesity drug market with an estimated share of 38.3% in 2025 stems from a well-established healthcare infrastructure, strong pharmaceutical industry presence, and comprehensive government policies supporting obesity management. The region benefits from high healthcare expenditure and widespread awareness about obesity-related health risks. The presence of major pharmaceutical companies such as Novo Nordisk, Pfizer, and Eli Lilly drives innovation and extensive clinical trials, ensuring a robust pipeline of anti-obesity therapies. Additionally, favorable regulatory frameworks by agencies like the USFDA facilitate faster drug approvals.

For instance, on November 8, 2023, the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition, such as high blood pressure or type 2 diabetes. Zepbound, developed by Eli Lilly and Co., is already approved as Mounjaro for improving blood sugar in adults with type 2 diabetes. The approval addresses the growing need for treatments in the face of increasing obesity rates in the U.S.

Asia Pacific Anti-Obesity Drug Market Analysis and Trends

The Asia Pacific region is expected to exhibit the fastest growth owing to rising obesity prevalence driven by urbanization, lifestyle changes, and increasing disposable incomes with a share of 24.2% in 2025. Governments across countries like China, India, Japan, and South Korea are implementing awareness campaigns and supporting healthcare reforms to tackle obesity, creating a conducive environment for market expansion. The growing middle-class population demanding better healthcare options fuels demand. Additionally, the presence of emerging pharmaceutical companies and increased foreign direct investments contributes to market dynamism. Trade liberalization and improved healthcare infrastructure, coupled with collaborations between multinational and local companies, further accelerate growth in this region.

For instance, on June 03, 2025, Biocon Limited, a global biopharmaceutical company known for affordable biologics and generics, received approval in India for its diabetes treatment Liraglutide. Its subsidiary, Biocon Pharma, also secured approval for the 6 mg/ml injectable formulation in pre-filled pens and cartridges. This generic version of Victoza is indicated for Type 2 diabetes in adults and children over 10, alongside diet and exercise. Liraglutide is a synthetic GLP-1 analog given as a once-daily injection. First approved in the EU in 2009 and the US in 2010 for diabetes, it later received U.S. FDA approval in 2014 and EMA approval in 2015 for weight management in obese or overweight adults with related conditions.

Anti-Obesity Drug Market Outlook for Key Countries

U.S. Anti-Obesity Drug Market Trends

The U.S. remains the most crucial market within North America, supported by significant investments in research and development and a proactive regulatory regime. Industry giants like Pfizer, Novo Nordisk, and Eli Lilly dominate, offering a broad portfolio that includes GLP-1 receptor agonists and other advanced therapeutics. The country’s high obesity rates, combined with increased health awareness and reimbursement schemes, have significantly contributed to the growing adoption of obesity treatments.

For instance, in September 2024, new research from the U.S. Centers for Disease Control and Prevention (CDC) reveals that nearly 1 in 10 adults in the U.S. report severe obesity, with women being nearly twice as likely as men to be affected. While the overall obesity rate remains high at about 40%, the proportion of those with severe obesity has increased over the past decade. Severe obesity is strongly linked to higher risks of cardiovascular disease and diabetes.

China Anti-Obesity Drug Market Trends

China's rapid urbanization and changing diets have fueled a growing obesity crisis, with projections showing that by 2030, 70.5% of adults and 31.8% of children may be obese. In response, the government is focusing on health reforms and chronic disease management, driving the demand for anti-obesity medications. Companies like Novo Nordisk are forming joint ventures with local firms to cater to Chinese patients. Experts also propose creating integrated chronic disease clinics to combine weight management with treatments for conditions like diabetes and heart disease, offering a more holistic approach to healthcare. This positions China as a key market for obesity treatments in the coming years.

For instance, in May 2025, according to the National Library of Medicine, China is facing a growing obesity crisis, with predictions showing that by 2030, 70.5% of adults and 31.8% of children may be obese. To address this, experts propose creating integrated chronic non-communicable disease (NCD) management clinics that combine weight management with the treatment of obesity-related conditions like diabetes and heart disease. These clinics, using multidisciplinary teams, would offer personalized care, improve outcomes, and optimize healthcare resources, providing a more holistic approach to China’s rising health challenges.

Germany Anti-Obesity Drug Market Trends

Germany’s anti-obesity drug market benefits from a robust healthcare infrastructure, extensive insurance coverage, and strong regulatory support for innovative therapies. Pharmaceutical companies including Bayer and Pfizer play prominent roles by offering a variety of prescription anti-obesity drugs. The country’s focus on lifestyle-related disease management, coupled with government campaigns promoting healthier living, aids market penetration.

For instance, in April 2025, according to data published by Lancet under the journal of public health in Germany, Germany's public health system faces challenges despite high spending, with rising rates of lifestyle-related diseases like obesity, smoking, and heart disease. In response, the government has increasingly focused on managing these diseases through campaigns promoting healthier living. For instance, recent initiatives have aimed to reduce alcohol consumption and encourage healthier eating habits, particularly among youth. The government is urged to strengthen coordination, increase funding for prevention programs, and develop a comprehensive national public health strategy to tackle these growing health issues.

India Anti-Obesity Drug Market Trends

The India Anti-Obesity Drug Market is estimated to be valued at USD 1.24 Bn in 2025 and is expected to reach USD 4.38 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 19.7% from 2025 to 2032.

Market Trends

India Specific Drug Approved Matrix (Parameters can vary based on availability)

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Physician Opinion on Anti-Obesity Drugs in India

Effectiveness

GLP-1 Agonists (Saxenda, Wegovy) Recognized as significant advancements in obesity treatment, offering substantial weight loss (10-15%+ of body weight). Physicians consider them "game-changers" for eligible patients due to their superior efficacy compared to other options like Orlistat.

Orlistat Viewed as effective for modest weight loss (5-10%), but its efficacy is highly dependent on patient adherence to a low-fat diet. Often seen as a "first-line but unsatisfactory" option due to gastrointestinal side effects.

Tirzepatide Dual-action drug, targeting both glucose metabolism and appetite regulation. It’s praised for its efficacy, but side effects and high cost are concerns.

Cost & Accessibility

Cost Barriers The prohibitive cost of Saxenda and the anticipated high price of Wegovy are major hurdles, with most physicians citing these drugs as inaccessible for over 95% of the Indian population. This has led to widespread off-label use of diabetes GLP-1 doses.

Need for Affordability Physicians emphasize the necessity for drastic price reductions, inclusion in public health schemes, or development of affordable biosimilars/generics for these drugs to have a real public health impact in India.

Side Effects & Safety Concerns

Orlistat Generally safe but causes gastrointestinal side effects (e.g., oily spotting, flatus, fecal urgency), which often lead to discontinuation. Long-term use may require monitoring for fat-soluble vitamin deficiencies.

GLP-1 Agonists (Saxenda, Wegovy, Tirzepatide) These drugs are generally well-tolerated, with side effects primarily involving nausea, vomiting, and, in some cases, gallbladder issues. Physicians are concerned about the potential for hypoglycemia in diabetic patients taking other glucose-lowering medications.

Patient Selection & Compliance

Lifestyle Foundation Physicians emphasize that no drug can replace the necessity of diet modification and physical activity. Medications should be considered adjuncts, not cures. Successful outcomes are reliant on lifestyle changes.

Patient Compliance There is frustration with patients seeking "magic pills" without commitment to lifestyle changes. Effective treatment requires careful patient selection based on BMI and comorbidities, along with managing patient expectations.

Personalization A personalized approach is crucial, with many physicians advocating for tailored treatment plans that consider individual needs and comorbidities.

Frustration with OTC Market

Physicians are frustrated with the unregulated OTC "weight-loss" products, many of which are seen as ineffective or dangerous due to adulterants like Sibutramine, DNP, or steroids.

Anticipation for Future Drugs

There is significant anticipation for the launch of Wegovy, with hopes that it will provide better efficacy and tolerability compared to Saxenda. Future treatments like oral GLP-1s and Tirzepatide are also anticipated but tempered by concerns over cost and accessibility.

General Feedback

Anti-obesity drugs are generally seen as effective when combined with lifestyle modifications. However, concerns around side effects, cost, and patient adherence remain significant. Personalized treatment and better education for physicians on obesity management are key to improving treatment outcomes.

End User Feedback and Unmet Needs in the Global Anti-Obesity Drug Market

• End users in the global anti-obesity drug market, including healthcare providers, pharmaceutical companies, and patients, have shared a wide range of feedback regarding the performance, accessibility, and operational challenges of obesity drugs. Positive feedback often revolves around the effectiveness and ease of use of newer treatments like GLP-1 receptor agonists, particularly Semaglutide and Tirzepatide, which have shown promising results in both weight loss and management of associated metabolic conditions.
• For instance, healthcare providers have reported high satisfaction with Tirzepatide's efficacy in promoting weight loss among patients with severe obesity, with some noting a reduction of over 15% of body weight. This success has led to increased adoption among patients who are struggling with weight loss using traditional methods. However, a recurring concern from both patients and healthcare providers is the cost and accessibility of these treatments, especially with newer and more potent options. High out-of-pocket costs, limited insurance coverage, and slow adoption in emerging markets are often cited as barriers, making it difficult for a broader patient base to access these treatments.
• Despite the growing adoption of effective anti-obesity drugs, significant unmet needs persist. Patients and healthcare providers frequently mention the lack of long-term data regarding the safety and sustainability of weight loss with newer medications, which creates uncertainty about long-term usage. Additionally, there is an increasing demand for customized treatment regimens that cater to individual metabolic profiles. Many patients struggle with finding the right dosage or formulation, indicating a need for more personalized approaches.
• Furthermore, affordability remains a significant concern, particularly for low-income populations and in developing markets where access to these treatments is limited. Addressing these gaps through advancements in personalized medicine, cost-effective drug formulations, and greater healthcare support could open new growth opportunities, improve patient adherence, and inspire innovation in the development of more affordable, accessible, and customizable solutions in the anti-obesity space. Manufacturers and policymakers who prioritize these needs are likely to enhance patient retention and foster long-term market expansion.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• On June 24, 2025, Novo Nordisk, a global leader in diabetes and obesity care, launched its anti-obesity injection Wegovy (semaglutide 2.4 mg) in India. Wegovy is the first drug in the country approved both for chronic weight management and for reducing the risk of major cardiovascular events in people with existing heart disease. The once-weekly injectable, already available in many international markets, is being introduced with a gradual dose escalation approach to help patients adapt clinically over time. The launch reflects growing demand for advanced weight-loss treatments in India’s rapidly expanding obesity care market.
• In March 2025, U.S.-based pharma giant, Eli Lilly and Company, a leader in innovative diabetes treatments, launched its obesity and diabetes drug Mounjaro (tirzepatide) in India after securing approval from the Central Drugs Standard Control Organisation. Mounjaro, available as a single-dose vial, targets both GIP and GLP-1 hormone receptors to help manage Type 2 diabetes and excess weight. In clinical trials, adults using the drug alongside diet and exercise lost an average of 15.4 kg to 21.8 kg over 72 weeks, depending on the dosage.
• In February 2025, Mankind Pharma, a leading Indian pharmaceutical company, is developing an oral anti-obesity drug targeting GPR119, a receptor involved in weight management. The drug, initially developed for diabetes, has shown promising Phase 1 results and is now in Phase 2 trials in Australia. If successful, it could become the first small-molecule pill-based treatment for obesity, offering a new alternative to injectable options like GLP-1 inhibitors.
• In November 2023, Eli Lilly and Company received U.S. FDA approval for Zepbound (tirzepatide), a groundbreaking obesity treatment that activates both GIP and GLP-1 hormone receptors. Zepbound is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also have weight-related health conditions like hypertension, type 2 diabetes, or cardiovascular disease. In clinical trials, patients lost an average of 48 lbs at the highest dose. This new treatment, when combined with a reduced-calorie diet and exercise, offers a powerful option for long-term weight management.

Top Strategies Followed by Global Anti-Obesity Drug Market Players

• Established market leaders leverage their immense financial strength and scale to dominate through massive R&D investments and global expansion. For example, Novo Nordisk invests billions annually to develop and market blockbuster GLP-1 agonists like Wegovy (semaglutide for obesity) and Ozempic (semaglutide for diabetes), while advancing next-gen candidates such as CagriSema. To meet overwhelming demand, they form critical manufacturing partnerships with companies like Catalent and aggressively expand global production (e.g., new plants in Denmark, France, Ireland, and the U.S.) and distribution, rapidly launching Wegovy in key growth markets like China and Japan.
  • Similarly, Eli Lilly drives innovation with Zepbound (tirzepatide for obesity) and Mounjaro (tirzepatide for diabetes), investing heavily in next-phase candidates like retatrutide. They secure production capacity through alliances with firms like Nexus Pharmaceuticals and expand manufacturing infrastructure (e.g., a major new facility in North Carolina) to accelerate global launches in regions such as the U.K. and EU.

• Mid-level players focus on affordability, strategic partnerships, and regional opportunities to compete. Companies like Vivus (now part of Icahn Enterprises) historically offered lower-cost oral alternatives such as Qsymia (phentermine/topiramate ER), targeting price-sensitive segments.
  • Amneal Pharmaceuticals, a generics specialist, leverages its manufacturing expertise to challenge incumbents, exemplified by filing one of the first abbreviated new drug applications (ANDAs) for generic semaglutide injectable in the U.S. Regional leaders such as Eurofarma concentrate on high-need markets like Latin America (e.g., Brazil), addressing local obesity challenges through branded generics and biosimilars, often via partnerships with multinationals for local manufacturing or in-licensing.

• Small-scale players in the global anti-obesity drug market differentiate themselves by focusing on specialized product features or innovative therapeutic approaches that larger competitors might overlook. These smaller companies leverage cutting-edge technologies like personalized medicine and novel delivery systems. A prime example is Calibrate, a startup offering a comprehensive metabolic reset program combining medication, lifestyle adjustments, and digital health tools to provide a holistic treatment for obesity. Another example is The Qsymia (phentermine/topiramate) combination from VIVUS, which has focused on developing a unique oral weight-loss solution with a novel delivery system. These small companies are agile and can quickly adapt to market trends, making innovation a core component of their strategy.

Market Report Scope

Market Dynamics

To learn more about this report, Download Free Sample

Anti-Obesity Drug Market Driver - Rising Global Obesity Prevalence

The escalating prevalence of obesity worldwide has emerged as a significant factor propelling the demand for anti-obesity medications. Urbanization, sedentary lifestyles, unhealthy dietary patterns, and genetic predispositions have collectively contributed to a steady rise in obesity rates across diverse age groups and regions. As obesity is closely linked with numerous chronic conditions such as type 2 diabetes, cardiovascular diseases, and certain cancers, there is an increasing urgency among healthcare providers and patients to seek effective treatment options beyond conventional lifestyle modifications. This growing health concern has heightened awareness about the benefits of pharmacological interventions, encouraging individuals who struggle with weight management to turn to anti-obesity drugs as adjunct therapy.

For instance, in May 2025, according to the WHO, 1 in 8 people globally were living with obesity, with 2.5 billion adults overweight, including 890 million with obesity. The prevalence of obesity has more than doubled since 1990, while adolescent obesity has quadrupled. In children, 390 million were overweight, with 160 million living with obesity. Obesity significantly increases the risk of diseases like diabetes, heart disease, and certain cancers. The condition is diagnosed using Body Mass Index (BMI), with overweight defined as a BMI of 25 or greater, and obesity as 30 or greater in adults. The global rise in obesity, particularly in low- and middle-income countries, poses serious health challenges.

Anti-Obesity Drug Market Opportunity - Development of New Drug Formulations

The global anti-obesity drug market is experiencing significant opportunities due to the growing prevalence of obesity and an increasing demand for safer, more effective, and patient-friendly treatments. Advancements in pharmaceutical technology and a better understanding of obesity's complex causes have led to innovative drug formulations. These include extended-release formulations, combination therapies, and targeted molecular treatments designed to improve efficacy, minimize side effects, and enhance patient adherence.

A notable example of these developments is Eli Lilly’s Mounjaro KwikPen, which received approval from India's Central Drugs Standard Control Organization (CDSCO) on June 26, 2025. This once-weekly prefilled injector, designed for both type 2 diabetes and obesity, expands the drug's availability from the initial 2.5mg and 5mg vials to include six strengths (2.5, 5, 7.5, 10, 12.5, and 15mg). The new KwikPen offers a more personalized and convenient dosing option, reflecting the broader trend in the industry towards more adaptable and user-friendly drug delivery systems.

Analyst Opinion (Expert Opinion) 

• The global anti-obesity drug market is experiencing robust growth, driven by several key factors, including advancements in pharmacological treatments such as GLP-1 receptor agonists and dual-agonist therapies. The increasing prevalence of obesity worldwide, coupled with the rising awareness of its associated health risks like diabetes and heart disease, is further fueling market expansion. Regulatory support from agencies like the USFDA, which has fast-tracked approval for promising treatments, and technological innovations in drug delivery systems are additional catalysts. However, challenges such as high treatment costs, limited accessibility in emerging markets, and the lack of long-term clinical data on newer treatments remain significant barriers.
• Emerging opportunities in the market lie in the development of personalized treatment plans and affordable drug formulations that cater to diverse patient populations. Notable conferences like the Obesity Week 2022 and European Congress on Obesity have served as critical platforms for discussing breakthroughs and challenges within the industry, contributing to knowledge-sharing and policy development. Case studies such as the introduction of Mounjaro (Tirzepatide), which has shown significant weight loss results, and initiatives like the National Obesity Care Week are reshaping public and governmental attitudes towards obesity treatment, thus offering avenues for future market growth.

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Prescription Drugs
  • Over-the-Counter (OTC) Drugs
•  Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • GLP-1 Receptor Agonists
    • Semaglutide
    • Liraglutide
    • Tirzepatide
  • MC4R (Melanocortin-4 Receptor) Agonists
    • Setmelanotide
  • Lipase Inhibitors
    • Orlistat
  • Noradrenergic & Serotonergic Drugs
    • Phentermine
    • Diethylpropion
    • Phendimetrazine
  • Combination Therapies
    • Phentermine/Topiramate
    • Naltrexone/Bupropion
    • Others
  • Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
    • Empagliflozin
    • Canagliflozin
  • Bile Acid Sequestrants
    • Colesevelam
  • Amylin Analogs
    • Pramlintide
  • Others (Late Phase Drugs, etc.)
•  Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
  • Others (Transdermal)
•  Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Brand
  • Generic
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Geriatric
  • Pediatric
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Novo Nordisk
  • GlaxoSmithKline
  • AstraZeneca
  • Pfizer
  • Merck & Co.
  • Sanofi
  • Amgen
  • Eli Lilly and Company
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Abbott Laboratories
  • Orexigen Therapeutics
  • Zafgen
  • Rhythm Pharmaceuticals
  • Currax Pharmaceuticals

Sources

Primary Research Interviews

• Interviews with healthcare providers
• Patient focus groups
• Interviews with pharmaceutical industry experts

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)

Trade Publications

• Pharmaceutical Technology
• Drug Development and Delivery
• PharmaTimes
• Medical Marketing and Media (MM&M)

Academic Journals

• The Lancet Diabetes & Endocrinology
• Obesity Reviews
• Journal of Clinical Endocrinology & Metabolism
• Diabetes Care
• Journal of Obesity

Reputable Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• The Washington Post

Industry Associations

• Obesity Medicine Association (OMA)
• American Association of Clinical Endocrinologists (AACE)
• World Obesity Federation (WOF)
• European Association for the Study of Obesity (EASO)

Public Domain Resources

• National Health Service (NHS)
• National Center for Biotechnology Information (NCBI)
• U.S. Department of Health and Human Services (HHS)

Proprietary Elements

• CMI Data Analytics Tool Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years